Skip to search formSkip to main contentSkip to account menu

Imetelstat

Known as: DNA, d(3'-amino-3'-deoxy-P-thio)(T-A-G-G-G-T-T-A-G-A-C-A-A), 5'-[O-[2-hydroxy-3- [(1-oxohexadecyl)amino]propyl] hydrogen phosphorothioate] 
A synthetic lipid-conjugated, 13-mer oligonucleotide N3'-P5'-thio-phosphoramidate with potential antineoplastic activity. Complementary to the… 
National Institutes of Health

Related topics

Related topics

8 relations

Narrower (3)

AMG 706motesanibmotesanib diphosphate
Imetelstat SodiumNCIt Antineoplastic Agent Terminologyanalogs & derivatives

Broader (2)

IndolesNiacinamide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Evolving therapies for lower-risk myelodysplastic syndromes
The development in the therapeutic landscape of myelodysplastic syndromes (MDS) has substantially lagged behind other hematologic… 
2019
2019
Novel therapies in low- and high-risk myelodysplastic syndrome
ABSTRACT Introduction: Myelodysplastic syndromes (MDS) comprise a heterogeneous group of myeloid neoplasms with diverse clinical… 
2019
2019
PS1456 FAVORABLE OVERALL SURVIVAL OF IMETELSTAT-TREATED RELAPSED/REFRACTORY MYELOFIBROSIS PATIENTS COMPARED WITH CLOSELY MATCHED REAL WORLD DATA
• Myelofibrosis (MF), parꢀcularly Intermediate-2 (Int-2) or High-Risk disease per Dynamic Internaꢀonal Prognosꢀc Scoring System… 
Review
2018
Review
2018
Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are…
BACKGROUND: Patients with TD lower-risk (LR)-MDS relapsed or refractory to ESA have limited treatment options. Imetelstat is a… 
2018
2018
Transient Telomerase Inhibition with Imetelstat Impacts DNA Damage Signals and Cell-Cycle Kinetics
Telomerase is the ribonucleoprotein reverse transcriptase that catalyzes the synthesis of telomeres at the ends of linear… 
2017
2017
Efficacy and Safety of Imetelstat in RBC Transfusion-Dependent (TD) IPSS Low/Int-1 MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agents (ESA) (IMerge)
Background: There are limited treatment options for anemic patients with lower-risk MDS who are relapsed after or are refractory… 
2015
2015
TR-11A MOLECULAR BIOLOGY AND PHASE II STUDY OF IMETELSTAT (GRN163L) IN CHILDREN WITH RECURRENT OR REFRACTORY CENTRAL NERVOUS SYSTEM (CNS) MALIGNANCIES: A PEDIATRIC BRAIN TUMOR CONSORTIUM STUDY
INTRODUCTION: Telomerase activation is critical in many cancers including CNS tumors making telomerase inhibition a potential… 
2014
2014
Imetelstat, a Telomerase Inhibitor, Therapy for Myelofibrosis: A Pilot Study
Background : Current drugs in myelofibrosis (MF), including JAK inhibitors, do not induce complete or partial remissions… 
2012
2012
Imetelstat Rapidly Induces and Maintains Substantial Hematologic and Molecular Responses in Patients with Essential Thrombocythemia (ET) Who Are Refractory or Intolerant to Prior Therapy: Preliminary…
Abstract 179 Background: Myeloproliferative neoplasms (MPNs), such as essential thrombocythemia (ET), are driven by neoplastic… 
2012
2012
The Telomerase Inhibitor, Imetelstat, Rapidly Reduces Myeloma Cancer Stem Cells (CSCs) in a Phase II Trial
Abstract 4898 Despite improved response rates with the use of novel agents, the vast majority of patients with multiple myeloma… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)